Immune Checkpoints: The Rising Branch in Cancer Immunotherapy

Author:

Nurlaila Ika

Abstract

In the cancer therapy realm, concepts of immunotherapy rose as a response to emerging adverse effects caused by conventional therapies, which to some cases even more quality-of-life-reducing than the cancer itself. Immunotherapy is aimed to systematically enhance immunity to eradicate cancerous cells without harming healthy neighbor cells. In this platform, immune checkpoint molecules are under massive explorations and have been thought to be bringing excellent outlook clinically. These molecules hinder anticancer immunity. As a result, cancer growth is favored. Therefore, inactivation of immune checkpoint by blocking engagement of checkpoint receptors and their cognate ligands will restore the anticancer functions of immune system elements; hence, they can reclaim their power to eradicate cancers. Each checkpoint possesses specific downstream mechanism for which the inhibitors are formulated. In this chapter, we discuss four major checkpoints in the context of general characteristics, structures, and their roles in some cancers. Relevant recent progress in respective checkpoint molecules is also discussed to broaden our horizon on how cancers and immune checkpoint molecules are at interplay.

Publisher

IntechOpen

Reference75 articles.

1. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. The AAPS Journal. 7 Mar 2021;23(2):39. doi: 10.1208/s12248-021-00574-0. PMID: 33677681; PMCID: PMC7937597

2. Kuo AS, Dusan H, Aldrich JM. Critical care anesthesiology. In: Gropper MA, Miller RD, Cohen NH, Eriksson LI, Anesthesia M, Chapter B, et al., editors. Miller’s Anesthesia [Internet]. 9th ed. California, USA: Elsevier, Inc.; 2020. pp. 2654-2670. Available from: https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323596046000833

3. Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. Pharmacy and Therapeutics. 2012;37(9):503-530

4. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Research. 2020;30(8):660-669

5. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3